Recent Advances in Pretargeted Strategy for Cancer Theranostics
ChemMedChem · 18.11.2024 · 19 (22)
DOI: 10.1002/cmdc.202400462 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 12.09.2024. Verfasst von Yuyang Tian und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Cen…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Joint Funds for the innovation of science and Technology in Fujian province, State Key Laboratory of Analytical Chemistry for Life Science.
Abstract (Originalsprache)
In nuclear medicine, theranostic probes that combine nuclear imaging capabilities with therapeutic functions have shown promise for the diagnosis and treatment of cancers. Nevertheless, the development of theranostic probes may be constrained by two principal factors: (1) the discrepancy between the slow accumulation time of the probes in the tumours and the short‐lived radionuclides, and (2) the suboptimal imaging/treatment effect and high radioactive toxicity caused by long‐lived radionuclides. In recent years, pretargeted strategy has been proposed as a potential solution to solve these problems. In the pretargeted strategy, two components consisting of a tumour‐targeting vector (e. g., antibody) and a radionuclide are injected separately, which can then couple in the tumour tissues to trap radionuclides for nuclear imaging and/or therapy. This two‐step process allows for the independent optimization of the pharmacokinetics of them in vivo, benefiting to improve nuclear imaging and/or therapy of tumours in vivo. In this concept, we will discuss the principle of the pretargeted strategy, with a focus on the discussion of different tumour‐targeting vectors, including antibody‐mediated delivery, nanoparticle‐mediated delivery, metabolic glycan labeling‐mediated accumulation, and enzyme‐triggered in situ self‐assembly‐mediated retention. Finally, we will discuss the current challenges and perspectives on their applications for cancer theranostics in clinics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China.
- Department of Traditional Chinese Medicine, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
ORCID-Profile: Deju Ye
Förderung
- National Natural Science Foundation of China
- Joint Funds for the innovation of science and Technology in Fujian province
- State Key Laboratory of Analytical Chemistry for Life Science
- Excellent Research Program of Nanjing University
Zitieren
APA
Tian, Y., Huang, Z., Luo, J., & Ye, D. (2024). Recent Advances in Pretargeted Strategy for Cancer Theranostics. ChemMedChem, 19(22). https://doi.org/10.1002/cmdc.202400462
Vancouver
Tian Y, Huang Z, Luo J, Ye D. Recent Advances in Pretargeted Strategy for Cancer Theranostics. ChemMedChem. 2024;19(22). doi:10.1002/cmdc.202400462
BibTeX
@article{Tian2024,
author = {Tian, Yuyang and Huang, Zheng and Luo, Jiewei and Ye, Deju},
title = {Recent Advances in Pretargeted Strategy for Cancer Theranostics},
journal = {ChemMedChem},
year = {2024},
volume = {19},
number = {22},
doi = {10.1002/cmdc.202400462}
}
EUVIMED